The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study
Objective: to assess pain dynamics, daily functional activity of joints, quality of life, and treatment satisfaction in patients with knee and hip osteoarthritis (KOA and HOA), who long take a combined glucosamine (GA) and chondroitin sulfate (CS) drug in routine clinical practice.Patients and metho...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1050 |
| _version_ | 1797876677242519552 |
|---|---|
| author | A. M. Lila L. I. Alekseeva K. A. Telyshev A. A. Baranov E. A. Trofimov |
| author_facet | A. M. Lila L. I. Alekseeva K. A. Telyshev A. A. Baranov E. A. Trofimov |
| author_sort | A. M. Lila |
| collection | DOAJ |
| description | Objective: to assess pain dynamics, daily functional activity of joints, quality of life, and treatment satisfaction in patients with knee and hip osteoarthritis (KOA and HOA), who long take a combined glucosamine (GA) and chondroitin sulfate (CS) drug in routine clinical practice.Patients and methods: An interim analysis of data from an open multicenter prospective non-interventional study that is being conducted in the Russian Federation was carried out. The study included patients with Kellgren–Lawrence Stages I–III KOA or HOA, who were treated with a combined GA and CS drug (Theraflex®). The interim analysis was based on the data obtained at 16–24 weeks of treatment (Visit 2) in 542 patients (50% of the total sample).Results and discussion. A study group included patients with KOA (n=399) or HOA (n=143) from 43 centers in Russia. At visit 2, the KOA/HOA patients showed positive changes in all subscales of the Knee disability and Osteoarthritis Outcome Score (KOOS/Hip disability and Osteoarthritis Outcome Score (HOOS) questionnaires compared to the baseline level. The proportion of patients with a ≥20% increase in different subscale scores ranged from 42.6 to 67.4% for KOA and from 47.6 to 66.4% for HOA.Most (89.1%) patients took Theraflex® for ≥3 months. 76,1% of patients were satisfied with treatment efficiency. Adverse events (AEs) related to treatment were recorded in 16 (3.0%) patients and included mainly gastrointestinal tract disorders in 12 (2.2%) cases.Conclusion. The results obtained at 16–24 weeks of Theraflex® treatment are indicative of a decrease in the frequency and intensity of pain and other symptoms of OA, as well as increases in joint functional activity and quality of life in patients with KOA or HOA after the first cycle of therapy. The majority of the patients were satisfied with the treatment. The incidence of drug-related AEs was low, while their nature was consistent with information on the drug's side effects. |
| first_indexed | 2024-04-10T02:06:24Z |
| format | Article |
| id | doaj.art-770fcc107d0c4f2fb4010eb2affcecde |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:24Z |
| publishDate | 2020-09-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-770fcc107d0c4f2fb4010eb2affcecde2023-03-13T08:39:27ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-09-01143717810.14412/1996-7012-2020-3-71-782283The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational studyA. M. Lila0L. I. Alekseeva1K. A. Telyshev2A. A. Baranov3E. A. Trofimov4ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииObjective: to assess pain dynamics, daily functional activity of joints, quality of life, and treatment satisfaction in patients with knee and hip osteoarthritis (KOA and HOA), who long take a combined glucosamine (GA) and chondroitin sulfate (CS) drug in routine clinical practice.Patients and methods: An interim analysis of data from an open multicenter prospective non-interventional study that is being conducted in the Russian Federation was carried out. The study included patients with Kellgren–Lawrence Stages I–III KOA or HOA, who were treated with a combined GA and CS drug (Theraflex®). The interim analysis was based on the data obtained at 16–24 weeks of treatment (Visit 2) in 542 patients (50% of the total sample).Results and discussion. A study group included patients with KOA (n=399) or HOA (n=143) from 43 centers in Russia. At visit 2, the KOA/HOA patients showed positive changes in all subscales of the Knee disability and Osteoarthritis Outcome Score (KOOS/Hip disability and Osteoarthritis Outcome Score (HOOS) questionnaires compared to the baseline level. The proportion of patients with a ≥20% increase in different subscale scores ranged from 42.6 to 67.4% for KOA and from 47.6 to 66.4% for HOA.Most (89.1%) patients took Theraflex® for ≥3 months. 76,1% of patients were satisfied with treatment efficiency. Adverse events (AEs) related to treatment were recorded in 16 (3.0%) patients and included mainly gastrointestinal tract disorders in 12 (2.2%) cases.Conclusion. The results obtained at 16–24 weeks of Theraflex® treatment are indicative of a decrease in the frequency and intensity of pain and other symptoms of OA, as well as increases in joint functional activity and quality of life in patients with KOA or HOA after the first cycle of therapy. The majority of the patients were satisfied with the treatment. The incidence of drug-related AEs was low, while their nature was consistent with information on the drug's side effects.https://mrj.ima-press.net/mrj/article/view/1050остеоартрит коленного суставаостеоартрит тазобедренного суставанаблюдательное исследованиелечениетерафлекс<sup>®</sup> |
| spellingShingle | A. M. Lila L. I. Alekseeva K. A. Telyshev A. A. Baranov E. A. Trofimov The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study Современная ревматология остеоартрит коленного сустава остеоартрит тазобедренного сустава наблюдательное исследование лечение терафлекс<sup>®</sup> |
| title | The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study |
| title_full | The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study |
| title_fullStr | The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study |
| title_full_unstemmed | The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study |
| title_short | The efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis: intermediate results of a Russian observational study |
| title_sort | efficiency of treatment with a combined chondroitin sulfate and glucosamine hydrochloride drug for knee and hip osteoarthritis intermediate results of a russian observational study |
| topic | остеоартрит коленного сустава остеоартрит тазобедренного сустава наблюдательное исследование лечение терафлекс<sup>®</sup> |
| url | https://mrj.ima-press.net/mrj/article/view/1050 |
| work_keys_str_mv | AT amlila theefficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT lialekseeva theefficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT katelyshev theefficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT aabaranov theefficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT eatrofimov theefficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT amlila efficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT lialekseeva efficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT katelyshev efficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT aabaranov efficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy AT eatrofimov efficiencyoftreatmentwithacombinedchondroitinsulfateandglucosaminehydrochloridedrugforkneeandhiposteoarthritisintermediateresultsofarussianobservationalstudy |